Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756375 | 0.87 | CA12 (0.47) | DPP4CA1CA2CA12CA7 | |
| SCHEMBL30469443 | 0.87 | CA12 (0.47) | DPP4CA1CA2CA12CA7 | |
| SCHEMBL4123831 | 0.86 | DPP4 (0.51) | DPP4CA1CA2CA12CA7 | |
| SCHEMBL30460582 | 0.85 | DPP4 (0.39) | DPP4CA1CA2CA12CA7 | |
| Hydrochloric Acid SCHEMBL21711861 | 0.85 | CA12 (0.46) | DPP4CA1CA2CA12CA7 | |
| SCHEMBL27150109 | 0.85 | DPP4 (0.50) | DPP4CA1CA2CA12CA7 | |
| SCHEMBL1028046 | 0.84 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29559628 | 0.84 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1198863 | 0.84 | CA12 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3495778 | 0.84 | DPP4 (0.53) | DPP4CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12570646-B2 | Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2026-03-10 | — | — | US | disclosed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4680602-A1 | HETEROCYCLIC COMPOUNDS AS SELECTIVE HDAC6 INHIBITORS | Miralinc Pharma, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3921310-B1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA S L (ES) | 2026-01-14 | — | — | EP | disclosed |
| EP-4673444-A1 | OXADIAZOLE DERIVATIVE COMPOUNDS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2026-01-07 | — | — | EP | disclosed |
| EP-4642461-A1 | COMPOSITIONS FOR PREVENTING AND TREATING RENAL FAILURE (RF) | Chong Kun Dang Pharmaceutical Corp. (KR) | 2025-11-05 | — | — | EP | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250319093-A1 | COMPOSITIONS FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS (IPF) | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2025-10-16 | — | — | US | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| WO-1999026923-A1 | PARA-AMINOMETHYLARYL CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| US-5639906-A | Fluorescent and NMR sensitive pH indicators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| US-5466687-A | Anticholesterol agents | DR. KARL THOMAE GMBH (DE) | 1995-11-14 | — | — | US | disclosed |
| EP-0596326-B1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | THOMAE GMBH DR K (DE) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994018168-A1 | INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-18 | — | — | WO | disclosed |
| EP-0596326-A1 | Arylidene-1-azacycloalkanes and arylalkyl-1-azacycloalkanes, their salts, medicaments containing the same, use thereof and precesses for their production | Dr. Karl Thomae GmbH (DE) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319093-A1 | COMPOSITIONS FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS (IPF) | CFTR, MMP1, MACF1 | DPP4 2423/4885CA1 4631/4885CA2 2900/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | DPP4 678/4885CA1 2888/4885CA2 1795/4885 |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC11 | DPP4 3606/4885CA1 222/4885CA2 1137/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | DPP4 24/4885CA1 4374/4885CA2 2749/4885 |
| US-12570646-B2 | Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | HDAC6, HDAC3, HDAC1 | DPP4 1984/4885CA1 681/4885CA2 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.